A new study drug for autoimmune diseases that are hard to treat
Part of Bones, joints & muscles, Brain & nervous system, Eyes & vision, Immune system & allergy, Kidney & urinary, Lungs & breathing, Mouth & dental, Skin, Women’s health & pregnancy clinical trials.
This trial tests an experimental medicine (BMS-986553) for people with autoimmune diseases that have not improved with other treatments. It aims to see if the drug is safe and helpful for conditions like lupus, myositis, scleroderma, rheumatoid arthritis, and Sjögren's disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have one of these autoimmune diseases: lupus (SLE), myositis (IIM), scleroderma (SSc), rheumatoid arthritis (RA), or Sjögren's disease.
- Your disease must be 'refractory', meaning it has not gotten better with standard treatments.
- You cannot have any other autoimmune or immune system disease.
- You must meet the official classification criteria for your disease, which your doctor can confirm.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing an experimental drug for safety in people with certain autoimmune diseases—like myositis, scleroderma, or Sjögren's disease—as well as in healthy volunteers. It aims to find out if the drug is safe enough to study further.
This study is testing an experimental medicine called PF-08154225 to see if it can help treat several autoimmune conditions, including rheumatoid arthritis, lupus, and related disorders. It might reduce disease activity or symptoms in people who have not found relief from other treatments.
This trial tests a new drug called GSK5926371 for people with certain autoimmune diseases that affect the joints, skin, and other tissues. It aims to see if the drug is safe and how well it works.
This trial tests an investigational drug called AZD5492 for people with active lupus, inflammatory myositis, or rheumatoid arthritis who haven't responded well to other treatments. It aims to see if the drug is safe and how it works in the body.
This early-stage trial tests a new treatment called MTS109 for autoimmune diseases (like lupus, muscle inflammation, scleroderma, vasculitis, or Sjögren's syndrome) that haven't responded well to standard medications. The goal is to see if MTS109 can help control disease that keeps flaring or getting worse despite current treatments.
This study tests a new drug called HBM7020 to see if it is safe and how well it is absorbed by the body. It is for healthy people and people with certain autoimmune diseases like lupus, scleroderma, rheumatoid arthritis, or Sjögren's disease.
Hear when a new Systemic Lupus Erythematosus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.